摘要
目的:探讨MID1在人大肠癌中表达的临床意义及其对术后生存时间的影响.方法:采用SP免疫组织化学法检测109例大肠癌手术切除组织标本中MID1的表达,分析MID1的表达与大肠癌的关系,用KaplanMeier和Cox回归分析法进行生存分析.结果:MID1的表达对大肠癌的术后的生存时间有显著影响(P<0.05);与大肠癌的淋巴结转移情况呈显著性负相关(r=-0.204,P=0.034<0.05);与大肠癌的浸润深度呈显著性负相关(r=-0.223,P=0.020<0.05);与大肠癌的分化程度呈显著性正相关(r=0.236,P=0.014<0.05);MID1的表达与大肠癌的年龄、性别及其病理类型没有关系.Kaplan-Meier生存曲线结果显示,随访期内MID1高中低各组7年累积生存率分别为69.2%、45.0%、30.0%;高中低各表达组患者术后平均生存时间分别为:91.101mo±6.127mo,69.389mo±7.512mo,50.358mo±8.091mo,Log-rank检验证明,整体水平及各组间水平均有统计学意义(P<0.05);经多因素Cox回归分析发现,MID1低表达、淋巴结的转移可显著增加患者的死亡风险(P<0.05).结论:MID1可以作为大肠癌分化、侵袭、淋巴结转移以及预后的一项指标.
AIM:To detect the expression of midline 1 (MID1) in human colorectal carcinoma and to assess its prognostic significance.METHODS:Immunohistochemistry was used to detect the expression of MID1 protein in colorectal carcinoma specimens (n=109).The relationship between the survival of patients with colorectal cancer and the expression of MID1 was investigated.Survival analyses were performed using the Kaplan-Meier method and Cox regression model.RESULTS:MID1 expression significantly affected the survival of patients with colorectal carcinoma (P0.05).MID1 expression had a significantly negative correlation with lymph node metastasis (r=-0.204,P=0.034) and depth of invasion (r=-0.223,P=0.020),but was significantly positively correlated with differentiation de-gree (r=0.236,P=0.014).MID1 expression had no relationship with sex,age or tumor pathologic type.Kaplan-Meier analysis indicated that the 7-year cumulative survival rates for patients with high,medium and low MID1 expression were 69.2%,45.0% and 30.0%,respectively,and their mean survival time was 91.101 mo±6.127 mo,69.389 mo±7.512 mo,50.358 mo±8.091 mo.CONCLUSION:MID1 expression can be used as a parameter for the judgment of colorectal carcinoma differentiation,invasion and lymph node metastasis,and as a useful prognostic marker in patient with colorectal carcinoma.
出处
《世界华人消化杂志》
CAS
北大核心
2012年第2期113-118,共6页
World Chinese Journal of Digestology
关键词
MID1
免疫组织化学
大肠癌
预后
Midline 1
Immunohistochemistry
Colorectal carcinoma
Prognosis